• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharma Supply Chains: From Fragile to Agile

    Advanced Manufacturing and a Roadmap to the Facility of the Future

    Solving Pharma’s Underlying Rebate Leakage Problem

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Revolutionizing Pharma’s Supply Chain
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems

    "3 Key Trends" with Srinivasan Shanmugam
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Pharmaceutical Continuous Manufacturing: USP Technical Guide

    Mikart Expands Production and Packaging Capabilities

    Flavor Masking for Rx and OTC Drugs

    Prefilled Syringe Production: Filling a Need with Modern Equipment

    Making the Complex, Simple: A Roadmap for Your OSD Journey
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Modern Partnerships with CROs

    Merck KGaA, Quris-AI Expand Collaboration

    BioCity, AstraZeneca Partner on Treatment of Advanced HCC
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Rentschler Biopharma’s ATMP UK Facility Receives MHRA Approval

    Aurisco's Manufacturing Site in China Clears FDA Inspection

    LighthouseAI Secures $2.25M Investment to Grow Supply Chain Products

    Valisure, DoD Conduct Pharmaceutical Quality Risk Assessment Study
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Quotient Sciences

    LOTTE BIOLOGICS

    TaiMed Biologics

    Societal CDMO

    INCOG BioPharma Services
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Quotient Sciences

    LOTTE BIOLOGICS

    TaiMed Biologics

    Societal CDMO

    INCOG BioPharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Advanced Therapy Manufacturing Trends

    A look at chain of identity and custody in personalized therapies, plus their core differences from traditional pharma

    Advanced Therapy Manufacturing Trends
    Advanced Therapy Manufacturing Trends
    Figure 1. COI for an Autologous Cell Therapy Drug Product. Complete traceability for the lifetime of the patient—ensuring patient safety for multiple products and doses—starts with establishing a COI/COC system that can scale as new types of products enter the advanced therapies landscape, or as patients undergo more than one dosing or treatment.
    Heidi Hagen, Chief Strategy Officer and Co-founder, Vineti01.28.20
    In pharmaceutical manufacturing, Chain of Identity and Chain of Custody may not be new, but in advanced therapy manufacturing, they take on a whole new significance. Why? Because in personalized therapies, a person is a key part of the process.

    With any pharmaceutical product, a key aspect of regulatory compliance is generating and maintaining a complete record of the lot genealogy, which includes the Chain of Identity (COI) and Chain of Custody (COC). This is true for cell therapies, gene therapies, and personalized cancer vaccines as well, and due to the unique and complex nature of these products, the requirements are even more stringent and detailed.

    This commentary presents an overview of COI and COC, what lot genealogy looks like in traditional pharmaceuticals, and then highlights the major differences for personalized therapies.

    What are COI and COC?
    Here are definitions commonly used in the industry:

    Chain of Identity (COI): The permanent and transparent association of a donor’s unique identifiers to their tissue or cells (raw material), and the resulting drug product, for the entire process from order through manufacturing to treatment and post-treatment monitoring. For example, an autologous donor’s patient number should be linked to their unique donation number and manufacturing batch number as part of the COI.

    Chain of Custody (COC): The permanent capture of data related to who handled the collection and/or product, what actions were performed, and the location/date/time of the actions from the start of tissue/cell collection through product administration.

    The core COI is the overarching record for an individual patient or donor and is used as a foundation to 1) link all of an individual’s collections and product journeys to them, AND 2) link together (associate) all the key data for an individual collection and product journey, clearly demonstrating a complete COI and COC.

    The COI record has multiple links and layers, and sometimes applies to multiple doses or treatments. But it always ties back to the same patient or donor.
    What is lot genealogy and how is it different in personalized therapies?

    Lot genealogy is a fundamental regulatory requirement for all pharmaceuticals and a cornerstone for ensuring patient safety. It is simply a record of all the materials, processes, testing, and outputs of a pharmaceutical product. This record demonstrates GMP compliance, process control, and product quality.

    For a traditional pharmaceutical product, lot genealogy is typically done on a large batch basis (or by “lot”) and is relatively straightforward. At a high level, it looks like this:
    • Raw materials are procured in bulk from GMP suppliers;
    • Ingredients added to a batch are recorded throughout the process;
    • Activities performed by personnel are recorded in the batch record; and
    • A certificate of analysis is generated to show that the product meets pre-defined specifications.
    These basic steps naturally encompass collecting the data related to COC. COI and COC are sub-parts of the overall lot genealogy.

    All the pieces of lot genealogy remain in place for personalized therapies, and the underlying principle is the same. As stated by the EMA in guidance related to Advanced Therapy Medicinal Products (ATMPs), “The records should enable the entire history of a batch to be traced.”1 But there are some significant differences, especially the addition of a stand-alone COI for each patient, and the emphasis on traceability of the live human cells.

    COI and COC of the human cells are the “backbone” of patient safety in advanced therapies. The EMA’s advanced therapy guidance document further states: “Compliance with GMP is an essential part of the pharmaceutical quality system. In particular...it should be ensured that: adequate systems are implemented to ensure traceability of the ATMPs and of their starting and critical raw materials...The manufacturer should ensure that the following data is retained for a minimum of 30 years...Donation identification code received from the tissue establishment/blood establishment...and internal code (or other identification system) that is generated by the manufacturer to unequivocally identify the tissues/cells used as starting materials throughout the entire manufacturing process up to the point of batch release...”2 

    There are three reasons for this:
    • Adding live human cells to a product significantly increases the variability of raw materials;
    • It is critical that patients are treated with the drug product containing the cells or formulation meant specifically for them, whether it’s their own cells (autologous therapies) or donor cells (allogeneic therapies with some matching), to avoid safety consequences such as product rejection or anaphylactic shock; and
    • The complexity of the process exponentially increases because of how the cells are procured and transported, the careful handling and processing required, and the potential for multiple batches and/or doses per patient. Each product journey is fundamentally different and unique.
    A closer look at the drivers for lot genealogy enhancements in cell and gene therapies
    Cell therapies use live human cells as a key raw material, and manufacturing batch sizes are typically quite small—in autologous cell therapies, and some allogeneic cell therapies, there is one complete batch per donor/patient. These are major differences from traditional drug products.

    Unlike traditional raw materials, the live human cells are not standardized or well characterized. There can be wide variability in cells from patient to patient, especially in populations of patients with serious, advanced health conditions such as late-stage cancer. It is important to capture and track key pieces of data related to this raw material, not only to ensure that patients are ultimately treated with the right product, but also to ensure drug product quality, regulatory compliance, and accurate health and outcomes information. Again, the EMA is quite clear on this point as well when they state, “Good documentation is an essential part of the quality system and is a key element of GMP. The main objective of the system of documentation utilized must be to establish control, monitor and record all activities which directly or indirectly may affect the quality of the medicinal products. Records required to ensure traceability should also be kept.”3

    The live cells used in personalized therapies differ from traditional raw materials in another significant way. In other situations, human cells or tissues are not typically collected under GMP conditions, and the process for including them in the batch of drug product is more complex. Cell or tissue collection is typically done at a research hospital, outpatient clinic, or blood collection facility. These organizations have high quality standards, but not the same as the rigor of GMP. Providing these organizations with the tools, procedures, and training to comply with GMP, and to properly track COI and COC, is an important aspect of ensuring a successful and compliant product journey each and every time.

    Additionally, once the cells are procured, there are typically special storage and transportation steps to ensure cell viability and to move them from the point of collection to the manufacturing facility. This must all be performed and tracked meticulously using GMP standards to ensure a complete COI, COC, and overall lot genealogy.

    The live cells used in personalized therapies differ from traditional raw materials in another significant way. In other situations, human cells or tissues are not typically collected under GMP conditions, and the process for including them in the batch of drug product is more complex. Cell or tissue collection is typically done at a research hospital, outpatient clinic, or blood collection facility. These organizations have high quality standards, but not the same rigor as GMP. Providing these organizations with the tools, procedures, and training to comply with GMP, and to properly track COI and COC, is an important aspect of ensuring a successful and compliant product journey each and every time. Additionally, once the cells are procured, there are typically special storage and transportation steps to ensure cell viability and to move them from the point of collection to the manufacturing facility. This must all be performed and tracked meticulously using GMP standards to ensure a complete COI, COC, and overall lot genealogy.

    All records of any products started in a cell therapy process, even if they are not finished or administered, must have a complete COI. The EMA has clearly articulated the requirement for a completely linked COI: “A system that enables the bidirectional tracking of cells/tissues contained in ATMPs from the point of donation through manufacturing, to the delivery of the finished product to the recipient should be created.”4 The FDA, which has also been evaluating regulatory requirements for advanced therapies, is preparing to release a new set of guidances later this year.

    The window of traceability can be much longer for a cell therapy than for a traditional pill as well. The COI becomes part of the health system once the drug product is administered to the patient. They have received modified human cells and this must be monitored and traceable for the patient’s lifetime.

    Conclusion
    COI and COC are simply an expansion of the traditional lot genealogy concept to adapt to the biological complexity of personalized therapies. The COI and COC for a personalized therapy must be captured in a single record relating to a specific donor or patient and it must demonstrate a safe and compliant product journey. Each product journey is different—it happened under different conditions, was handled by different people, and had its own dedicated processing steps and test results. Regardless, the standard for lot genealogy remains the same, which is to demonstrate GMP compliance, process control, and product quality—and protect the safety of each and every patient. 

    References
    1. European Commission, 2017. Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products (EudraLex, The Rules Governing Medicinal Products in the European Union, Volume 4, Good Manufacturing Practice, Section 6.3, Sub-section 6.26, P. 33). Brussels, Belgium. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/2017_11_22_guidelines_gmp_for_atmps.pdf
    2. European Commission, 2017. Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products (EudraLex, The Rules Governing Medicinal Products in the European Union, Volume 4, Good Manufacturing Practice, Section 1.2, Sub-section 1.24 viii, P. 7; Section 6.6, Sub-section 6.37 i, P. 36). Brussels, Belgium. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/2017_11_22_guidelines_gmp_for_atmps.pdf
    3. European Commission, 2017. Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products (EudraLex, The Rules Governing Medicinal Products in the European Union, Volume 4, Good Manufacturing Practice, Section 6.1, Sub-section 6.10, P. 30). Brussels, Belgium. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/2017_11_22_guidelines_gmp_for_atmps.pdf
    4. European Commission, 2017. Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products (EudraLex, The Rules Governing Medicinal Products in the European Union, Volume 4, Good Manufacturing Practice, Section 6.6, Sub-section 6.35, P. 36). Brussels, Belgium. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/2017_11_22_guidelines_gmp_for_atmps.pdf

    Heidi Hagen is the chief strategy officer and a co-founder of Vineti. Over the course of her career, she has overseen the operations and delivery for more than 100,000 doses of cell therapy. If you’d like to learn more about how Vineti’s software platform supports scalable COI and COC for cell and gene therapies, visit http://vineti.com.
    Related Searches
    • facility
    • cell therapies
    • quality
    • process control
      Loading, Please Wait..
      Breaking News
      • Univercells Expands into the U.S. With New Offices in Andover, MA
      • Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
      • Ionis, Roche Partner on RNA-targeted Programs for AD and HD
      • Sanner Group Opens Second Manufacturing Facility in China
      • Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
      View Breaking News >
      CURRENT ISSUE

      September 2023

      • Pharma Supply Chains: From Fragile to Agile
      • Overcoming Stressors in Knowledge Transfer
      • Innovations in Pharma Packaging
      • HPAPI Manufacturing Trends
      • Sustainable Packaging in Pharma: No Longer a Pipe Dream
      • Revolutionizing Pharma’s Supply Chain
      • Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges
      • Solving Pharma’s Underlying Rebate Leakage Problem
      • Advanced Manufacturing and a Roadmap to the Facility of the Future
      • View More >

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      D2C Supplement Brand Launches Blood Sugar Support Supplement, Gluco-Control
      Natrol Launches First Non-Melatonin Sleep Supplement
      Metagenics Releases Consumer Survey on Menopausal Support Supplement
      Coatings World

      Latest Breaking News From Coatings World

      Coating Additives Market Worth $10.5B by 2028: MarketsandMarkets
      California Sports Surfaces Celebrates 70 Years
      ROSS Offers Cost-Effective, Expertly Reconditioned Equipment
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      MPO's Most-Read Stories This Week—Sept. 30
      Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman
      SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Univercells Expands into the U.S. With New Offices in Andover, MA
      Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
      Ionis, Roche Partner on RNA-targeted Programs for AD and HD
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      MAV Beauty Recruits Former Elizabeth Arden CEO Scott Beattie
      YSL Beauty Taps Finn Wolfhard, Lil Yachty & More for Fragrance Campaign
      74% of Makeup Users Open to Affordable ‘Dupes,’ Mintel Says
      Happi

      Latest Breaking News From Happi

      Is Dr. Barbara Sturm Skincare Considering a Sale?
      YSL Beauty Welcomes Five Foremost Artists to Represent New Fragrance
      Christian Siriano Appointed Olay’s First Chief Drop Officer
      Ink World

      Latest Breaking News From Ink World

      MicroDynamics, All Printing Resources Partner to Represent Veritas
      Weekly Recap: Wikoff Color, BASF, Latin America Top This Week’s Stories
      Siegwerk’s Climate Targets Validated by SBTi
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      SABIC and partners launch bio-based IML solution for food packaging
      tesa completes expansion of Michigan manufacturing facility
      Comexi and Asahi to host 'Effortless Platemaking' event
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Greentech Introduces Air Filter with Advanced Odor Elimination
      Ontex Divests Pakistan Operations to ASAIA Holding
      Goodnites Bedwetting Underwear Recognized by Good Housekeeping
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      ODT's Most-Read Stories This Week—Sept. 30
      Lazurite Adds Benchmark Medical as a Distributor for its ArthroFree Wireless Camera System
      ChitogenX Granted New U.S., Canadian ORTHO-R Patent
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: Mergers and Acquisitions, First Solar Top This Week’s Stories
      Jabil Posts Fourth Quarter, Fiscal Year 2023 Results
      Ink-Borne ‘Chiplets’ Could Lead to Printable Displays, Electronics and More

      Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login